Skip to main content

Table 3 Clinical and laboratory data among homozygous carriers of P2 allele versus heterozygous group and non-carriers

From: Interleukin-4 gene intron 3 VNTR polymorphism in adult acute myeloid leukemia

Variables P1P1 and P1P2 (n = 26) P2P2 (n = 34) P value
Age (years), Mean ± SD 37.1 ± 11.50 47.6 ± 14.70 0.004
Sex, n (%) 0.909
 Male 18 (69.2) 24 (70.6)
 Female 8 (30.8) 10 (29.4)
Extramedullary involvement, n (%) 0.700
 Positive 12 (46.2) 14 (41.2)
 Negative 14 (53.8) 20 (58.8)
TLC (× 103/µL), Median (IQR) 12.6 (4.5–30) 28 (15–130) 0.025
Hemoglobin (g/dL), 0.120
 Mean ± SD 7.82 ± 2.21 7.2 ± 2.1
Platelets (× 103/µL), × 109/L), Median (IQR) 66 (18 -141) 19 (13–62) 0.010
PB blasts (%) 0.005
Median (IQR) 20 (2–49) 58 (33–69)
BM blasts (%),Median (IQR) 60 (38–80) 80 (67–85) 0.023
FAB Subtype, n (%) 0.973
 M0, M1 6 (23.1%) 8 (23.5%)
 M2 14 (53.8%) 19 (55.9%)
 M4/5, M6, M7 6 (23.1%) 7 (20.6%)
Immunophenotyping, n (%)
 HLA-DR 22 (84.6) 31 (91.2) 0.432
 CD34 21 (80.8) 28 (82.4) 0.874
 MPOX 20 (76.9) 30 (88.2) 0.244
Cytogenetic risk groups, n (%)* 0.32
 Favorable 4 (19) 3 (10)
 Intermediate and poor 16 (61.53) 27 (90)
Complete remission 23 (88.55) 22 (64.7%) 0.035
  1. Bold values indicate significant p value
  2. *Six patients (23%) from (P1P2 + P1P1) group and four patients (11.76%) from P2P2 group were excluded due to non -provided data or failed cytogenetic analysis
  3. MPOX myeloperoxidase; Favorable cytogenetic markers: t(8;21), inv(16); Intermediate cytogenetic markers: normal karyotype, trisomy 8; Unfavorable cytogenetic markers t(11q23), t(9;11), monosomy7